Mode
Text Size
Log in / Sign up
Phase 3 N=720 Randomized Double-blind Supportive Care

Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge

Analgesia After ED Discharge for Extremity Injuries

Enrolled (actual)
720
Serious AEs
0.0%
Results posted
May 2018
Primary outcome: Primary: Difference in Pain Intensity Score Before and After Last Dose. — 7.6; 7.6; 7.9; 7.9 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Hydrocodone (first trial) (Drug); Codeine (first trial) (Drug); Oxycodone (for second trial) (Drug); Codeine (for second trial) (Drug); Oxycodone (third trial) (Drug); Hydrocodone (third trial) (Drug)
Age
Adult · 21+ yrs
Sex
All
Sponsor
Montefiore Medical Center
Primary completion
Nov 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Difference in Pain Intensity Score Before and After Last Dose.
7.6; 7.6; 7.9; 7.9; 7.8; 7.6
SECONDARY
Overall Satisfaction With the Pain Medicine
72; 66; 99; 91; 93; 97

Summary

There will be 3 randomized, double-blinded clinical trials to help determine which of commonly prescribed oral opioid combination is most effective in managing acute extremity pain after discharge from the adult emergency department. The first trial compares hydrocodone 5mg / acetaminophen 500mg to codeine 30mg/acetaminophen 300mg. The second trial compares oxycodone 5mg/acetaminophen 325mg to codeine 30mg/acetaminophen 300mg. The third trial compares oxycodone 5mg/acetaminophen 325 mg to hydrocodone 5mg/acetaminophen 325 mg.

Eligibility Criteria

Inclusion Criteria

  • patient has complaint of acute extremity pain (less than 7 days duration)
  • clinician plans to discharge on oral pain medication

Exclusion Criteria

  • patients on methadone
  • chronic pain condition such as sickle cell anemia or fibromyalgia
  • history of adverse reaction to one of the study medications
  • taken prescribed opioids in the past 24 hrs
  • have a medical condition that might alter the metabolism of one of the study medications (i.e. hepatitis, renal insufficiency, thyroid disease, Adrenal disease)
  • Take a medication that might interact with one of the study medications
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01402375). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search